Singular Genomics Systems (Singular Genomics Systems) Change In Receivables : $-0.12 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Singular Genomics Systems Change In Receivables?

Singular Genomics Systems's change in receivables for the quarter that ended in Mar. 2024 was $0.43 Mil. It means Singular Genomics Systems's Accounts Receivable declined by $0.43 Mil from Dec. 2023 to Mar. 2024 .

Singular Genomics Systems's change in receivables for the fiscal year that ended in Dec. 2023 was $0.35 Mil. It means Singular Genomics Systems's Accounts Receivable declined by $0.35 Mil from Dec. 2022 to Dec. 2023 .

Singular Genomics Systems's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.14 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Singular Genomics Systems's Days Sales Outstanding for the three months ended in Mar. 2024 was 28.28.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Singular Genomics Systems's liquidation value for the three months ended in Mar. 2024 was $74.98 Mil.

Singular Genomics Systems Change In Receivables Historical Data

The historical data trend for Singular Genomics Systems's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Singular Genomics Systems Change In Receivables Chart

Singular Genomics Systems Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-0.91

0.35

Singular Genomics Systems Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial													0.90	-0.02	-0.37	-0.17	0.43

Singular Genomics Systems Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12 Mil.

Singular Genomics Systems (NAS:OMIC) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Singular Genomics Systems's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.137	/	0.442	*	91
=	28.28

2. In Ben Graham's calculation of liquidation value, Singular Genomics Systems's accounts receivable are only considered to be worth 75% of book value:

Singular Genomics Systems's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	150.738	-	82.403	+	0.75 * 0.137	+	0.5 * 13.081
=	74.98

Singular Genomics Systems Change In Receivables Related Terms

Thank you for viewing the detailed overview of Singular Genomics Systems's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Singular Genomics Systems (Singular Genomics Systems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Singular Genomics Systems Inc (NAS:OMIC) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

3010 Science Park Road, San Diego, CA, USA, 92121

Website

https://www.singulargenomics.com

Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.

Executives

Andrew Spaventa	director, 10 percent owner, officer: Chief Executive Officer	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Eli N. Glezer	officer: Chief Scientific Officer	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Jyotsna Ghai	officer: Chief Operating Officer	3010 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Kim P. Kamdar	director	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Marcia Eisenberg	director	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Sam Ropp	officer: Chief Commercial Officer	3010 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Michael J Pellini	director	222 DUTTON MILL RD, WILLISTOWN PA 19380
Elaine R Mardis	director	301 MERRITT 7, NORWALK CT 06851
James E Flynn	10 percent owner, other: *Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
David Daly	officer: President and Chief Operating	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Vincent Brancaccio	officer: Vice President, HR	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Dalen Meeter	officer: Vice President, Finance	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Daralyn Durie	officer: General Counsel	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Jorge Velarde	officer: Senior Vice President	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
David L Barker	director	9885 TOWNE CENTRE DR, SAN DIEGO CA 92121